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Abstract
Aims/hypothesis There are limited data comparing dipeptidyl
peptidase-4 (DPP-4) inhibitors directly. We compared the
safety and efficacy of vildagliptin and sitagliptin in patients
with type 2 diabetes and severe renal impairment (RI).
Methods This study was a parallel-arm, randomised,
multicentre, double-blind, 24 week study conducted in 87 cen-
tres across Brazil and the USA. Patients with type 2 diabetes,
either drug naive or treated with any glucose-lowering agents,
who had inadequate glycaemic control (HbA1c 6.5–10.0%
[48–86 mmol/mol]) and an estimated GFR <30 ml min−1
[1.73 m]−2 were randomised (via interactive voice response
technology) to vildagliptin 50 mg once daily or sitagliptin
25 mg once daily. These doses are recommended in this patient
population and considered maximally effective. Participants,
investigators and the sponsor were blinded to group assign-
ment. Efficacy endpoints included change in HbA1c and fasting
plasma glucose (FPG) at all visits and the primary safety end-
point was assessment of treatment-emergent adverse events.
Results In total, 148 patients were randomised, 83 to
vildagliptin and 65 to sitagliptin. All patients were analysed.
After 24 weeks, the adjusted mean change in HbA1c was
−0.54% (5.9 mmol/mol) from a baseline of 7.52%
(59 mmol/mol) with vildagliptin and −0.56% (6.1 mmol/
mol) from a baseline of 7.80% (62 mmol/mol) with sitagliptin
(p=0.874). FPG decreased by 0.47±0.37 mmol/l with
vildagliptin and increased by 0.16±0.43 mmol/l with
sitagliptin (p=0.185). Both treatments were well tolerated
with overall similar safety profiles.
Conclusions/interpretation At their recommended doses for
severe RI, vildagliptin (50 mg once daily) compared with
sitagliptin (25 mg once daily) demonstrated similar efficacy
and both drugs were well tolerated. This study provides fur-
ther support for the use of DPP-4 inhibitors in patients with
severe RI.
Trial registration: ClinicalTrials.gov NCT00616811
(completed)
Funding: This study was planned and conducted by Novartis
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Introduction
Renal impairment (RI) is very common in patients with type 2
diabetes [1], as diabetes is the leading cause of kidney failure
and end-stage renal disease (ESRD) [2]. In particular, the
management of patients with type 2 diabetes and severe RI
poses a vast challenge, as therapeutic options are limited be-
cause of contraindications and/or increased risk of
hypoglycaemia in this patient populat ion [3, 4].
Hypoglycaemia is more common in patients with RI because
of decreased renal gluconeogenesis [5], and in particular,
overexposure to insulin secretagogues or exogenous insulin
is often associated with an increased risk of hypoglycaemia
[6].
Dipeptidyl peptidase-4 (DPP-4) inhibitors such as
vildagliptin and sitagliptin are generally well tolerated, and
are approved for use in patients with severe RI. Owing to their
glucose-dependent mechanism of action, they are generally
associated with a low risk of hypoglycaemia and are an attrac-
tive treatment option for these difficult-to-treat patients [7].
All DPP-4 inhibitors improve glycaemic control by extending
the meal-induced increases in glucagon-like peptide-1 (GLP-
1) and glucose-dependent insulinotropic polypeptide (GIP)
for several hours by slowing the rate of inactivation of these
peptides. There are differences in the mechanisms of action of
DPP-4 inhibitors, in particular their catalytic binding kinetics
[8], which may translate into clinical differences. For exam-
ple, vildagliptin blocks DPP-4 through substrate-like binding
to the active site of the enzyme for an extended time [8]. By
contrast, sitagliptin exerts its effect through competitive en-
zyme inhibition [8, 9]. Only vildagliptin has been shown to
block the inactivation of GLP-1 and GIP between meals and
overnight [8, 9]. However, there are limited data comparing
the various agents directly.
We report here the efficacy and safety/tolerability of
vildagliptin compared with sitagliptin in patients with type 2
diabetes and severe RI, with a focus on glycaemic control
relative to hypoglycaemic risk.
Methods
Study design This study was a multicentre, randomised, par-
allel-arm, double-blind, 24 week, clinical trial of vildagliptin
(50 mg once daily) and sitagliptin (25 mg once daily) in pa-
tients with type 2 diabetes and severe RI (ClinicalTrials.gov
registration no. NCT00616811). The primary objective of the
study was to evaluate the safety and tolerability of both treat-
ments in this patient population. The study was conducted
between January 2008 and October 2010. Participants were
recruited as outpatients in 87 centres across Brazil (6) and the
USA (81).
Key inclusion criteria for this study included age 18–
85 years, BMI 18–42 kg/m2, HbA1c 6.5–10.0% (48–
86 mmol/mol), type 2 diabetes either untreated (no glucose-
lowering medication in the past 8 weeks) or treated with a
stable dose of sulfonylurea, thiazolidinedione, meglitinide or
insulin, as monotherapy or in combination (for at least
4 weeks), and severe RI (estimated GFR [eGFR] by the
Modification of Diet in Renal Disease [MDRD] formula
<30 ml min−1 [1.73 m]−2). Patients were excluded if they
had a history of renal transplant, significant cardiovascular
history within 6 months, liver disease, abnormal liver function
tests (alanine transaminase [ALT] >2× upper limit of normal
[ULN], aspartate transaminase >2× ULN or total bilirubin
>2× ULN and/or direct bilirubin >ULN) or any treatment that
is contraindicated (i.e. metformin) in the severe RI population.
The initial protocol excluded patients undergoing any dialysis,
but it was subsequently amended to remove this restriction to
facilitate recruitment.
Patients continued their initial background treatment
throughout the study. After a 2 week, single-blind, placebo
run-in period, eligible patients were randomised using inter-
active voice response technology (IVRS) to receive either
vildagliptin (50 mg once daily) or sitagliptin (25 mg once
daily) for 24 weeks in addition to continuing their background
treatment, if applicable. IVRS assigned a randomisation num-
ber to the patient, which was used to link the patient to a
treatment arm and to specify unique medication numbers for
the first package of study drug to be dispensed to the patient.
This clinical trial targeted enrolling a population of approx-
imately 33% elderly women as a patient population consid-
ered more vulnerable. Therefore, patient randomisation was
stratified by a combined age and sex factor (≥65 year old
women versus others) and background glucose-lowering
medication. Randomisation procedures were performed by
the investigator or his/her delegate. The study drugs were
supplied by Novartis as tablets, and patients were instructed
to take one pill a day orally before breakfast. Patients, inves-
tigator staff, persons performing the assessments and data
analysts remained blinded to the identity of the treatment
from the time of randomisation until database lock. Both
medications were used at the doses recommended in the
label for patients with severe RI. Rescue medication (insu-
lin addition or intensification) could be administered on or
after week 4 if fasting plasma glucose (FPG) was
>15 mmol/l, after week 8 if FPG >13.3 mmol/l and after
week 16 if FPG >12.2 mmol/l.
Outcomes HbA1c and FPG were measured at all visits. An
analysis of responder rate was also performed to assess the
percentage of patients achieving HbA1c ≤6.5% (48 mmol/
mol) and <7.0% (53 mmol/mol). HbA1c and routine biochem-
istry laboratory assessments were performed by a central lab-
oratory (Covance, Indianapolis, IN, USA).
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For assessment of safety and tolerability all treatment-
emergent adverse events (AEs) were recorded and evaluated
by the investigator for severity and possible relationship to
study medication. Hypoglycaemia was defined as symptoms
suggestive of low blood glucose confirmed by a self-
monitored blood glucose measurement <3.1 mmol/l plasma
glucose equivalent.
Statistical analyses A total of 150 patients (in a 1.5:1 alloca-
tion ratio to vildagliptin 50 mg once daily and sitagliptin
25 mg once daily) were planned to be randomised.
Assuming an approximate 35% dropout rate (i.e. patients
who did not complete the 24 weeks of treatment), 90 patients
randomised to the vildagliptin group would provide approxi-
mately 58 patients who completed 24 weeks of treatment. A
sample size of 58 patients who completed the 24 week study
in the vildagliptin treatment group would have 83% power to
observe at least one AE with an underlying rate of 3%. For
efficacy variables (HbA1c and FPG), the adjusted mean
changes from baseline to endpoint (with last observation car-
ried forward) were compared between treatments using an
ANCOVA model, with the baseline value as the covariate,
and background therapy, pooled centre and treatment as the
classification variables. In addition, the time course of HbA1c
values and change from baseline by treatment were tabulated
and plotted. Efficacy data were censored at the start of rescue
medication. The values presented are means±SE unless oth-
erwise specified. The safety data were summarised descrip-
tively by treatment. Safety analyses were performed on all
collected data regardless of rescue medication.
Ethics and good clinical practice The study was conducted
in accordance with the Helsinki Declaration of 1975, as re-
vised in 2000 and 2008, and the International Conference on
Harmonization/Good Clinical Practice guidelines. The study
protocol was approved by an independent ethics committee/
institutional review board at each site and all patients provided
written informed consent.
Results
Patient disposition and patient demographic/clinical
characteristics A total of 148 patients with type 2 diabetes
and severe RI were randomised, 83 patients to vildagliptin
(50 mg once daily) and 65 patients to sitagliptin (25 mg once
daily), in addition to their stable background glucose-lowering
medication. Of the 148 randomised patients, 117 patients
completed the study, 64 (77.1%) in the vildagliptin group
and 53 (81.5%) in the sitagliptin group, with the most com-
mon reasons for discontinuation being withdrawal of consent
(vildagliptin 12.0%, sitagliptin 4.6%) and AEs (vildagliptin
4.8%, sitagliptin 6.2%) (Fig. 1). The recruited population with
severe RI also included a limited number of patients with
ESRD on haemodialysis (six patients in each treatment
group).
Table 1 summarises the demographic and clinical charac-
teristics of the patients in the randomised population as well as
baseline glucose-loweringmedication. There were no clinical-
ly meaningful differences between groups in the baseline
characteristics. Forty-six (31.1%) patients were elderly wom-
en (≥65 years). Mean eGFR (MDRD) was 19.7 ml−1 min
[1.73 m]−2 in the vildagliptin group and 20.4 ml min−1
[1.73 m]−2 in the sitagliptin group. Patients (48% men/52%
women) had a mean age of 66.8 years (with nearly two-thirds
≥65 years), mean BMI of 33.2 kg/m2 (with more than two-
thirds ≥30 kg/m2) and longstanding type 2 diabetes (mean
disease duration 19.2 years). Nearly two-thirds of the patients
were white, more than 20% were black and about 12% were
Hispanic/Latino. Before entering the study, almost all patients
(97.3%) were treated with one or more glucose-lowering
agents. About 80% of patients received insulin as either
monotherapy or combination therapy, at mean doses of
53 U/day in the vildagliptin group and 60 U/day in the
sitagliptin group. Mean HbA1c was 7.5% (58 mmol/mol) in
the vildagliptin group vs 7.8% (62 mmol/mol) in the
sitagliptin group and mean FPG was 8.1 and 7.7 mmol/l,
respectively.
Patients had concomitant medical conditions expected in
patients with type 2 diabetes and severe RI. Hypertension was
reported in more than 95%, dyslipidaemia in about 90% and
cardiac disorders in nearly 60% of the randomised patients.
Nearly all the patients received antihypertensive (95%) and
lipid-lowering (88%) medications and more than 60% were
taking platelet aggregation inhibitors.
Glycaemic control and hypoglycaemia The adjusted mean
changes in HbA1c and FPG during the 24 week treatment
period as well as the percentage of patients achieving a target
HbA1c ≤6.5% (48 mmol/mol) are represented in Fig. 2. The
adjusted mean change in HbA1c was −0.54%±0.12% (5.9±
1.3 mmol/mol) from a baseline of 7.52% (59 mmol/mol) in
the vildagliptin group and −0.56%±0.13% (6.1±1.4 mmol/
mol) from a baseline of 7.80% (62 mmol/mol) in the
sitagliptin group (p=0.874 for between-group difference;
Fig. 2a). A reduction in FPG of 0.47±0.37 mmol/l was seen
with vildagliptin, while a slight increase of 0.16±0.43 mmol/l
was found with sitagliptin. This difference did not reach sta-
tistical significance given the relatively small cohorts (p=
0.185 for between-group difference; Fig. 2b). The percentage
of patients achieving a target HbA1c ≤7.0% (53 mmol/mol)
was similar in both treatment groups (39% vs 40%); however,
the proportion of patients achieving a target HbA1c ≤6.5%
(48 mmol/mol) in the vildagliptin group was twice that in
the sitagliptin group (29.0% vs 14.3%; p=0.050; Fig. 2c).
Even though there was a trend towards lower FPG levels in
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the vildagliptin group, the incidence of hypoglycaemia was
similar between the two treatment groups (16% vs 15%).
Furthermore, as depicted in Table 2, several AEs probably
related to hypoglycaemia were reported less frequently in
the vildagliptin group than the sitagliptin group (33% vs
51%). This difference was primarily driven by AEs of hyper-
hidrosis, tremor and asthaenia, as well as asymptomatic low
blood glucose levels.
Overall safety and tolerability There were no important dif-
ferences in the overall AE profiles between vildagliptin and
sitagliptin. The incidence of AEs (82% vs 86%), serious AEs
(24% vs 23%) and discontinuations due to AEs (7% vs 9%)
were comparable for vildagliptin and sitagliptin. Deaths were
reported in two patients in each group (cardiac arrest and
septic shock in the vildagliptin group, and acute pulmonary
oedema and asphyxia in the sitagliptin group). Infections and
infestations (vildagliptin 35% vs sitagliptin 39%), skin and
subcutaneous tissue disorders (25% vs 28%), musculoskeletal
and connective tissue disorders (22% vs 23%), cardiac disor-
ders (13% vs 15%), hepatobiliary disorders (0.0% vs 2%) and
pancreatitis (0% in both groups) were reported with similar
frequencies in both groups. The most commonly reported AE
was peripheral oedema, which occurred at a similar frequency
in the vildagliptin (23%) and sitagliptin (25%) groups. No
deterioration of renal function was observed with either
vildagliptin or sitagliptin. Two patients on sitagliptin had
ALTelevations (one patient with ALT >3×ULN in the context
of a gastritis, one asymptomatic with ALT >5× ULN); both
events resolved on treatment. There were no such liver en-
zyme elevations on vildagliptin. While a limited number of
patients with ESRD on haemodialysis were included in the
study (n=6 in each group), the safety data did not indicate that
these patients receiving vildagliptin or sitagliptin were at an
increased risk compared with the overall population with RI.
Discussion
The study presented here is the first to directly compare effi-
cacy and safety/tolerability of two DPP-4 inhibitors, namely
vildagliptin and sitagliptin, in patients with type 2 diabetes and
severe RI. The overall HbA1c lowering effect was similar for
both drugs and both drugs were well tolerated.
Both drugs in this study were used at their expected max-
imal effective and recommended doses (in accordance with
Completed (n=64, 77.1%) Completed (n=53, 81.5%)
Assessed for eligibility (n=503)
Excluded (n=355)a
Not meeting inclusion criteria,or 
meeting exclusion criteria (n=353)
Consent withdrawal (n=16)
Other reasons (n=12)
Full analysis set (n=81)
Safety set (n=83)
Discontinued (n=19)
Adverse events (n=4) 
Death (n=2)
Lost to follow-up (n=1)
Withdrawal of consent (n=10)
Protocol deviation (n=2)
Other (n=0)




Lost to follow-up (n=1)
Withdrawal of consent (n=3)
Protocol deviation (n=1)
Other (n=1)
Allocated to sitagliptin 25 mg daily (n=65) 
Full analysis set (n=63)
Safety set (n=65)
Randomised (n=148)
Fig. 1 Flow diagram of patient
disposition. aMore than one
reason for discontinuing
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product labelling) for patients with severe RI. Vildagliptin is
mostly hydrolysed to inactive metabolites, with approximate-
ly 20% being excreted unchanged [10]. In patients with severe
RI, a 50 mg once daily dose of vildagliptin provides full effi-
cacy, as slower elimination effectively doubles the period of
time it prevents GLP-1 and GIP inactivation [10, 11]. The
HbA1c reductions seen with vildagliptin 50 mg once daily in
patients with severe RI were similar to the reductions observed
with vildagliptin 50 mg twice daily in patients with preserved
renal function [12], and also consistent with HbA1c reductions
initially shown in a large, placebo-controlled trial in 515 pa-
tients with type 2 diabetes and moderate or severe RI [11]. As
sitagliptin is essentially excreted unchanged by the kidney
(80% is excreted as the unchanged compound with only a
small fraction being metabolised) and peak plasma concentra-
tion (Cmax) increases approximately fourfold in patients with
severe RI, the expected maximal effective dose and the dose
recommended on the label in patients with severe RI for
sitagliptin is 25 mg once daily [13–16].
The comparative efficacy of 50 mg vildagliptin and 25 mg
sitagliptin cannot be determined from this study with certainty
as it was not powered to assess relatively small differences in
efficacy. In the current study, 80% of patients were on insulin
treatment, which likely blunts any differences associated with
extending the effects of GLP-1 with vildagliptin during the
overnight period. Still, the numerical reduction in FPG with
vildagliptin and the slight increase in FPG with sitagliptin are
consistent with an effect of vildagliptin during the overnight
period. A limitation of the study is that no postprandial blood
glucose profiles were obtained. However, studies comparing
vildagliptin and sitagliptin in patients with preserved renal
function did not find relevant differences in postprandial glu-
cose excursions [17, 18]. Therefore, it is unlikely that this
would be the case in our study in patients with RI. The
Table 1 Patient demographics, clinical characteristics and baseline glu-
cose-lowering therapy




eGFR (MDRD) (ml min−1
[1.73 m]−2)
19.7±6.4 20.4±5.9
Age (years) 66.7±8.8 66.9±9.6
≥65 51 (61.4) 40 (61.5)
Sex
Male 42 (50.6) 29 (44.6)
Female 41 (49.4) 36 (55.4)
Race
White 51 (61.4) 40 (61.5)
Black 19 (22.9) 15 (23.1)
Hispanic or Latino 10 (12.0) 7 (10.8)
Other 3 (3.6) 3 (4.6)
BMI (kg/m2) 32.7±5.0 33.8±4.8
HbA1c (%) 7.5±0.9 7.8±1.1
HbA1c (mmol/mol) 58±9.8 62±12.0
FPG (mmol/l) 8.1±3.2 7.7±3.0




None 3 (3.6) 1 (1.5)
Any 80 (96.4) 64 (98.5)
Insulin monotherapy 45 (54.2) 45 (69.2)
Insulin+SUs 11 (13.3) 7 (10.8)
Insulin+TZDs 7 (8.4) 2 (3.1)
SU monotherapy 9 (10.8) 7 (10.8)
Other 8 (9.6) 3 (4.5)
Randomised set
Data are means±SD or n (%)
SU, sulfonylurea; TZD, thiazolidinedione





































































Fig. 2 (a) Adjusted mean (SE) change in HbA1c from baseline with
vildagliptin 50 mg once daily (n=78) or sitagliptin 25 mg once daily
(n=62), p=0.874. (b) Adjusted mean (SE) change in FPG from baseline
with vildagliptin 50 mg once daily (n=79) or sitagliptin 25 mg once daily
(n=62), p=0.185. (c) Percentage of patients achieving HbA1c ≤6.5% and
≤7.0% with vildagliptin 50 mg once daily (n=69) or sitagliptin 25 mg
once daily n=56), p=0.050. Black bars, vildagliptin 50 mg once daily;
white bars, sitagliptin 25 mg once daily. To convert values for HbA1c in
DCCT % into mmol/mol, subtract 2.15 and multiply by 10.929
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percentage of patients achieving an HbA1c target of ≤6.5%
(48 mmol/mol) was higher in the vildagliptin group than the
sitagliptin group. This difference is unlikely to reflect a true
difference in efficacy between the drugs, and may be a conse-
quence of the slightly lower baseline HbA1c level in the
vildagliptin group. Interestingly, this higher responder rate
with vildagliptin was not associated with an increased risk of
hypoglycaemia with vildagliptin. Overall, the nearly identical
drops in HbA1c in our study indicate that the clinical efficacy
of both DPP-4 inhibitors is similar in spite of the differences
discussed above.
Both drugs were well tolerated. The incidence of
hypoglycaemia was similar between the two treatment groups
(16% vs 15%). These incidences are low given the vulnerable
patient population and that the majority of patients were on
insulin treatment. In a study with a similar design, the rates of
hypoglycaemia in vildagliptin-treated and placebo-treated pa-
tients were of similar magnitude as in our study [11]. The
longer extension of the meal-induced increase in GLP-1 and
GIP with vildagliptin was not associated with a safety concern
in the present study. Of interest, in a prior study in which
vildagliptin was dosed at either 50 mg once daily or 50 mg
twice daily (i.e. double the recommended dose on the global
label) in patients with ESRD, both dosing regimens were well
tolerated [19]. Thus, this and other clinical trials demonstrated
a good safety and tolerability profile of the entire DPP-4 in-
hibitor class in populations with severe RI, irrespective of the
degree of renal excretion or catalytic binding kinetics [7, 11,
16, 20–24].
In summary, this study demonstrates that vildagliptin
50 mg once daily and sitagliptin 25 mg once daily have
similar efficacy and safety profiles in patients with
severe RI, supporting the use of DPP-4 inhibitors in
patients with severe RI.
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